GlobeNewswire

Les Hôpitaux Shriners pour enfants Canada réalisent une première nationale en analyse du mouvement pédiatrique
15/09/2026
Seul centre d’analyse du mouvement au Canada agréé par la Commission for Motion Laboratory Accreditation (CMLA) MONTRÉAL, 15 sept. 2026 (GLOBE NEWSWIRE) -- Les Hôpitaux Shriners pour enfants Canada annoncent aujourd’hui [...]
Reflect Scientific Announces Liquid Nitrogen Cooling Technology for AI Data Center Applications
15/09/2026
OREM, Utah, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), today announced that its proprietary liquid nitrogen temperature control technology is available for application in the rapidly [...]
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
15/09/2026
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation ( [...]
Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna
15/09/2026
Egle to share clinical data on EGL-003, the company's most advanced Treg-selective IL-2 agonist for atopic dermatitis PARIS, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics (“Egle”), a clinical-stage biotechnology [...]
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
15/09/2026
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease [...]
Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease
15/09/2026
Rekha Abichandani, M.D., appointed Chief Medical Officer Enrollment nearing completion in Phase 2 basket study of WAL0921; initial data from diabetic kidney disease cohorts to be presented in fourth quarter 2026 Data [...]
The Waqf Fund acquires UK retail property to fund charitable work for generations to come
15/09/2026
MANCHESTER, United Kingdom, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The Waqf Fund announced a key real estate acquisition as a charity endowment. The fund has completed the £1.9 million purchase of a prime freehold retail [...]
Profusa, Inc. Receives Nasdaq Compliance Determination
15/09/2026
Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The [...]
Hummingbird Bioscience Appoints Dr. James Garner as President
15/09/2026
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“ [...]
TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026
15/09/2026
Final Phase 1 data provide clinical validation of CBP/p300 as a novel therapeutic target for overcoming transcriptional resistance in NSCLC TT125-802 demonstrates monotherapy anti-tumor activity across biologically [...]
Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program
15/09/2026
Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimester Dr. Gordon Sanghera CBE [...]
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
15/09/2026
Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE [...]
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
15/09/2026
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a [...]
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that [...]
Ontario Healthcare Stakeholders Unite on Shared Action Plan to Reduce Tobacco and Nicotine Dependence
15/09/2026
Vanguard healthcare, policy, and community stakeholders consolidate as newly formed Ontario Nicotine Action Table (ONAT) to build long-term plan for coordinated action TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- A broad [...]
Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab
15/09/2026
Strategic CDMO collaboration strengthens Axiom’s development infrastructure as the company prepares to advance its therapeutic pipeline. SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage [...]
PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers
15/09/2026
● PDUFA Target Action Date Set for March 16, 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolarityBio ® , a late-stage biotechnology company addressing unmet needs in wound healing through innovation in [...]
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
15/09/2026
Milestone continues the progress towards detection of all 20 amino acids by end of 2026 BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a [...]
Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS
15/09/2026
Enrollment advances into Cohort 2 of Phase 1 trial of RPT1G in relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS) U.S. Food and Drug Administration accepts Investigational [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum